No Data
No Data
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical Advances
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration
Oric Pharmaceuticals (ORIC) Gets a Buy From Wedbush
Express News | Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
loading...
No Data
No Data